TY - JOUR
T1 - Tumor necrosis factor-α decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt
AU - Medina, Edward A.
AU - Afsari, Robert R.
AU - Ravid, Tommer
AU - Sianna Castillo, S.
AU - Erickson, Kent L.
AU - Goldkorn, Tzipora
PY - 2005/6
Y1 - 2005/6
N2 - TNF-α is a mediator of insulin resistance in sepsis, obesity, and type 2 diabetes and is known to impair insulin signaling in adipocytes. Akt (protein kinase B) is a crucial signaling mediator for insulin. In the present study we examined the posttranslational mechanisms by which short-term (<6-h) exposure of 3T3-L1 adipocytes to TNF-α decreases Akt levels. TNF-α treatment both increased the ubiquitination of Akt and decreased its protein level. The decrease in protein was associated with the presence of an (immunoreactive) Akt fragment after TNF-α treatment, indicative of Akt cleavage. The broad-spectrum caspase inhibitor t-butoxycarbonyl-Asp(O-Me)- fluoromethyl ketone markedly suppressed these effects of TNF-α. The caspase-6 inhibitor Z-Val-Glu(OMe)-Ile-Asp(OMe)-CH2F potently suppressed Akt ubiquitination, degradation, and fragment formation, whereas the proteasome inhibitor Z-Leu-Leu-Leu-CHO modestly attenuated the decline in Akt levels. Exposure to TNF-α also enhanced the association of Akt with an E3 ligase activity. Adipocytes preexposed to TNF-α for 5 h and then stimulated with insulin for 30 min exhibited decreased levels of Akt, phosphorylated Akt, as well as phosphorylated Mdm2, which is a known direct substrate of Akt, and glucose uptake. Caspase inhibition attenuated these inhibitory effects of TNF-α. Collectively, our results suggest that TNF-α induces the caspase-dependent degradation of Akt via the cleavage and ubiquitination of Akt, which results in its degradation through the 26S proteasome. Furthermore, the caspase- and proteasome-mediated degradation of Akt due to TNF-α exposure leads to impaired Akt-dependent insulin signaling in adipocytes. These findings expand the mechanism by which TNF-α impairs insulin signaling.
AB - TNF-α is a mediator of insulin resistance in sepsis, obesity, and type 2 diabetes and is known to impair insulin signaling in adipocytes. Akt (protein kinase B) is a crucial signaling mediator for insulin. In the present study we examined the posttranslational mechanisms by which short-term (<6-h) exposure of 3T3-L1 adipocytes to TNF-α decreases Akt levels. TNF-α treatment both increased the ubiquitination of Akt and decreased its protein level. The decrease in protein was associated with the presence of an (immunoreactive) Akt fragment after TNF-α treatment, indicative of Akt cleavage. The broad-spectrum caspase inhibitor t-butoxycarbonyl-Asp(O-Me)- fluoromethyl ketone markedly suppressed these effects of TNF-α. The caspase-6 inhibitor Z-Val-Glu(OMe)-Ile-Asp(OMe)-CH2F potently suppressed Akt ubiquitination, degradation, and fragment formation, whereas the proteasome inhibitor Z-Leu-Leu-Leu-CHO modestly attenuated the decline in Akt levels. Exposure to TNF-α also enhanced the association of Akt with an E3 ligase activity. Adipocytes preexposed to TNF-α for 5 h and then stimulated with insulin for 30 min exhibited decreased levels of Akt, phosphorylated Akt, as well as phosphorylated Mdm2, which is a known direct substrate of Akt, and glucose uptake. Caspase inhibition attenuated these inhibitory effects of TNF-α. Collectively, our results suggest that TNF-α induces the caspase-dependent degradation of Akt via the cleavage and ubiquitination of Akt, which results in its degradation through the 26S proteasome. Furthermore, the caspase- and proteasome-mediated degradation of Akt due to TNF-α exposure leads to impaired Akt-dependent insulin signaling in adipocytes. These findings expand the mechanism by which TNF-α impairs insulin signaling.
UR - http://www.scopus.com/inward/record.url?scp=18844372276&partnerID=8YFLogxK
U2 - 10.1210/en.2004-1074
DO - 10.1210/en.2004-1074
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15746249
AN - SCOPUS:18844372276
SN - 0013-7227
VL - 146
SP - 2726
EP - 2735
JO - Endocrinology
JF - Endocrinology
IS - 6
ER -